<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From September 1983 to October 1988, 13 undifferentiated non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) of Burkitt's or non-Burkitt's type and 3 B cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> were treated with various multiagent chemotherapy regimens containing modest to high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (HDMTX) infusions </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> were children between the ages 2 years 8 months and 14 years 1 month </plain></SENT>
<SENT sid="2" pm="."><plain>The group included 13 boys and 3 girls </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were located primarily in the head and neck, 5; abdomen, 7; and lymph nodes, 1 </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical stages at diagnosis were stage I, 1; stage II, 6; stage III, 3; and stage IV, 3 </plain></SENT>
<SENT sid="5" pm="."><plain>The MTX infusion dosage ranged from 300 to 4,285 mg/M2, and the total cumulative dose per patient ranged from 750 to 30,168 mg/M2 </plain></SENT>
<SENT sid="6" pm="."><plain>Citrovorum Factor Rescue was given following <z:hpo ids='HP_0000001'>all</z:hpo> MTX infusions, except for 62 of the 300 mg/M2 infusions </plain></SENT>
<SENT sid="7" pm="."><plain>The serum MTX levels were monitored following <z:hpo ids='HP_0000001'>all</z:hpo> HDMTX </plain></SENT>
<SENT sid="8" pm="."><plain>The chemotherapy related toxicities were graded and analysed </plain></SENT>
<SENT sid="9" pm="."><plain>The clinical characteristics, which might predispose to HDMTX-related toxicities, were identified and are discussed </plain></SENT>
<SENT sid="10" pm="."><plain>Our data reveals the inpatient and interpatient variations in the kinetics of MTX </plain></SENT>
<SENT sid="11" pm="."><plain>There were no drug-related <z:hpo ids='HP_0011420'>deaths</z:hpo>, and the overall outcome of the patients was satisfactory </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that MTX infusion continues to play an important role in the current management of childhood B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>; however, obstacles still remain, especially for those with widespread B cell disease </plain></SENT>
</text></document>